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 AMP-activated protein kinase (AMPK) regulates cellular metabolism and 
promotes ATP production when energy is depleted.  Evidence suggests that AMPK may 
be involved in oxygen sensing by carotid body cells, which are responsible for regulating 
the breathing rate to maintain proper blood oxygen levels.  There are two isoforms of the 
catalytic α subunit, AMPKα1 and AMPKα2, which could be involved in oxygen 
sensing.  Here, the production of a short hairpin RNA (shRNA) targeting both catalytic 
isoforms of AMPK in human, mouse, and rat is described.  The shRNA causes significant 
knockdown of both isoforms of AMPKα  in mouse and human cells and a significant 
reduction in AMPK activity, measured as phosphorylation of a direct target.  This shRNA 
will be used to generate a rat model with tissue-specific knockdown of AMPKα1 and 2 
using a Cre-Lox recombination system to determine the role of AMPK in oxygen sensing 
by the carotid body.   
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AMP-activated protein kinase 
Regulating energy levels is an essential process that occurs in all living 
organisms.  AMPK (5’-adenosine monophosphate-activated protein kinase), also known 
as protein kinase, AMP-activated (PRKAA), is an enzyme that is conserved from yeast to 
humans and has important roles in sensing the energy status of the cell to maintain 
homeostasis [1-5].  AMPK has been linked to numerous disease states, including 
metabolic disorders and cancer, although its role is still not clear and appears to be 
context-dependent [6].  Functional AMPK is a heterotrimer that acts to regulate 
metabolism and is composed of three subunits, the catalytic alpha subunit and the 
regulatory beta and gamma subunits [3,7].  There are two isoforms of the AMPK alpha 
subunit, AMPKα1 and AMPKα2, and each isoform has been shown to have overlapping 
as well as distinct functions depending on the cell type [3,8-11].   
 
AMPK acts as a metabolic master switch regulating several intracellular systems 
including glucose uptake and β-oxidation of fatty acids.  AMPK inhibits fatty acid 
synthesis by phosphorylating acetyl-CoA carboxylase (ACC) at Ser79 [12].  The energy-
sensing capability of AMPK can be attributed to its ability to detect and react to 
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fluctuations in the AMP: ATP ratio.  Stressors, such as muscle contraction or ischemia, 
that deplete ATP in the cell result in an elevated AMP: ATP ratio, triggering AMPK 
activation.  AMPK is phosphorylated at Thr172 of the alpha subunit by LKB1, a known 
tumor suppressor [13], and calmodulin-dependent protein kinase kinase β (CaMKKβ) 
[14], and this phosphorylation is required for activation.  AMP activates AMPK by 
inhibiting the dephosphorylation of Thr172 by protein phosphatase-2C [5,8].  AMPK is 
also allosterically activated by AMP binding to the γ subunit [8].  Activated AMPK 
promotes ATP production and inhibits anabolic pathways that utilize ATP.   
 
Carotid body 
In addition to its other roles, AMPK may be involved in oxygen sensing.  The 
carotid body is a small paired sensory organ which is responsible for sensing oxygen 
levels in the carotid artery and signaling through the carotid sinus nerve to regulate the 
breathing rate in order to maintain oxygen homeostasis [15].  The carotid body is 
composed of two types of cells; type I cells sense oxygen through an unknown 
mechanism, and type II cells appear to provide support [16].  AMPK has been reported to 
couple hypoxic inhibition of mitochondrial oxidative phosphorylation to excitation of 
isolated rat carotid body type I cells [17].  To determine if AMPK is necessary for 
oxygen sensing by carotid body type I cells, we decided to generate an AMPK-deficient 
rat model to study the ability of the animals to respond to hypoxia.  Rats were chosen 
because the carotid body has been studied extensively in the rat [16].  It is not known 
which isoform of AMPKα may be involved in oxygen sensing or if they can both 
perform the same function in the carotid body.  For this reason, we wanted to inhibit both 
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isoforms.  These rats will be used to determine if AMPK is required in vivo for the 
carotid body to upregulate the breathing rate in response to hypoxia.   
 
Studying AMPK activity 
Multiple strategies to manipulate AMPK activity have been developed.  Drugs 
targeting AMPK, such as the activating drug AICAR (5-aminoimidazole-4-carboxyamide 
ribonucleoside) and inhibitor Compound C, have been identified, but these 
pharmacological agents have been shown to alter other processes in the cell as well [18-
19].  For example, AICAR is metabolized in the cell into an AMP analogue that is able to 
bind AMP-binding sites on other proteins and is also able to inhibit oxidative 
phosphorylation independent of its effect on AMPK [18].  Compound C has been shown 
to inhibit over 10 kinases, not just AMPK [19].  Therefore, these drugs do not specifically 
target AMPK, and alternate methods should be used to alter AMPK activity more 
precisely.  The generation of AMPKα1 (α1-/-) and α2 (α2-/-) knockout mice have 
established critical roles for AMPKα1 and AMPKα2 in the regulation of energy 
metabolism and oxygen sensing [3,9,20].  Double knockout of the AMPKα1 and 
AMPKα2 isoforms, simultaneously, results in lethality at embryonic day 10.5 [3], so this 
model system is not available to study functions that can be performed by both isoforms 
of AMPKα.  An alternative method to inhibit AMPKα1 and 2 is needed. 
 
RNA interference 
Another way to study the activity of AMPK is to block its expression using RNA 
interference.  RNA interference (RNAi) is a process by which double-stranded RNA 
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(dsRNA) molecules can regulate gene expression.  Small interfering RNAs (siRNAs), are 
synthetic, 21-nucleotide dsRNA molecules that are complementary to a mRNA transcript 
[21].  As shown in Figure 1, when siRNA is introduced into a cell, one strand is 
incorporated into the RNA-induced silencing complex (RISC) and binds the 
complementary mRNA [22].  This results in destruction of the mRNA transcript by a 
member of the Argonaute family of proteins [23], thus preventing translation into protein 
[24-25].  The effects of siRNA are transient because the siRNA molecules get diluted as 
the cells divide [26].  Therefore, this strategy is not useful for long-term studies.  
 
Short hairpin RNAs (shRNAs) are synthetic RNA molecules that have been 
modified to include a stem-loop-stem structure resembling the structure of naturally-
occurring microRNAs (miRNAs). As shown in Figure 1, the hairpin structure of shRNAs 
is cleaved by the enzyme Dicer in the cytoplasm into siRNA molecules [27].  shRNAs 
are transcribed from DNA templates such as plasmids, and this allows their expression to 
be stable and heritable in cell culture [28-31].  The RNA polymerase III promoters U6 
and H1, which are the promoters for the U6 small nuclear RNA and histone H1 
respectively, are commonly used to drive expression of shRNAs [32].  In addition, 
shRNAs can be used to generate transgenic animal models with knockdown of target 
proteins as an alternative to classic transgenic animal knockout models.  A number of 
silencing RNAs against AMPK have been generated [2,10,33-34], but there is no  
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Figure 1. Diagram of RNAi  pathway 
Diagram of the siRNA and shRNA pathways after transcription of an shRNA from a 
DNA template in the nucleus or introduction of synthetic siRNA molecules directly into 
the cytoplasm of the cell.  Arrows indicate molecules that must be introduced into the cell 
through transfection or another method to generate knockdown: DNA template such as a 













































reported sequence that is able to knock down both catalytic isoforms of AMPKα1 and 
AMPKα2 in multiple species.  For this reason, we designed an shRNA that is 
complementary to a sequence conserved between both catalytic isoforms in human, 
mouse, and rat and can be used in any of these three model systems. 
 
Cre-Lox system 
We will use Cre recombinase to direct the tissue-specific expression of an shRNA 
against AMPKα1 and 2.  Cre recombinase is an enzyme that catalyzes site-specific DNA 
recombination at sequences called LoxP sites [35].  LoxP sites are 34-basepair stretches 
of DNA containing two 13-basepair palindromes separated by an 8-basepair spacer, 
which confers directionality to the site; the region of DNA flanked by two LoxP sites is 
said to be “floxed” [36].  The Cre enzyme binds to LoxP sites in the DNA and aligns two 
sites in the same orientation.  It then catalyzes a recombination reaction in which the 
floxed DNA sequence and one of the two LoxP sites are excised from the DNA (Figure 
2).  This technique is used to delete genes or other stretches of DNA.  Cre recombinase 
has been used to create animal models with tissue-specific knockout of genes by mating 
mice with floxed genes to mice with tissue-specific expression of the Cre recombinase 
enzyme [originally described in 37].  The offspring resulting from the mating have 
knockout of the floxed gene only in tissues where Cre recombinase is expressed.  This 
powerful technique has been used numerous times to create animal models, especially 




Figure 2. Diagram of Cre recombinase-mediated recombination 
DNA recombination catalyzed by Cre recombinase at LoxP sites located between DNA 
regions A and B and regions B and C. Region B is the floxed DNA that is removed 
following binding of Cre recombinase at LoxP sites, looping of the DNA, aligning of the 
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Tissue-specific knockdown will be accomplished by disrupting the U6 promoter, 
which controls the expression of the shRNA, with a floxed sequence of DNA containing  
an RNA polymerase III stop sequence.  The promoter will not be active, and the shRNA 
will not be transcribed, unless the extra DNA is removed.  Figure 3 shows a diagram of a 
standard shRNA under control of the U6 promoter, an shRNA with a disrupted U6 
promoter, and a schematic of the recombination that would occur following the 
expression of Cre recombinase.  Tissue-specific expression of Cre recombinase will 
allow the promoter to be restored, and the shRNA will only be made in tissues that 
express Cre recombinase.   
 
The tissue-specific promoter that was chosen to direct the expression of Cre 
recombinase is the tyrosine hydroxylase (TH) promoter.  Tyrosine hydroxylase is an 
enzyme that catalyzes the conversion of L-tyrosine to DOPA, the rate-limiting step of 
catecholamine synthesis [38], and it is only expressed in carotid body type I cells [39] 
and in the brain and adrenal glands [40].  The shRNA will only be made in cells that 
express tyrosine hydroxylase.  The TH promoter was chosen because TH is known to be 
highly expressed in carotid body type I cells, and TH is frequently used as a marker for 
type I cells [39].  It is possible that there could be off-target effects on breathing 
regulation due to knockdown of AMPKα in other tissues.   
 
Both of the components necessary to generate tissue-specific knockdown of 




Figure 3. Structures of shRNA constructs 
(A) Structure of the shRNA under control of the U6 promoter. (B) Structure of the 
shRNA with disrupted U6 promoter. (C) Diagram of recombination that would occur 
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Figure 4 shows a diagram of this final construct.  The virus will contain both the shRNA 
with a disrupted U6 promoter and the Cre recombinase gene under control of the TH 
promoter.  Also shown in Figure 4 is a diagram of the recombination that would occur in 
tissues that activate the TH promoter and, therefore, express Cre recombinase.  This 
construct will be made into a lentivirus because the virus can be used to infect embryos in 




In this study, we demonstrate the production of a novel shRNA that 
simultaneously targets both AMPKα1 and α2 isoforms.  This shRNA is 100% 
complementary to a nucleotide sequence conserved in the human, mouse, and rat forms 
of the AMPKα1 and AMPKα2 mRNA and causes a significant reduction in AMPKα1 
and 2 protein levels.  Knockdown of AMPKα1 and 2 also reduces phosphorylation of 
ACC, a direct target of AMPK.  This new shRNA will be useful for analyzing the 
numerous functional roles of AMPKα1 and 2, and it will later be used to generate a 
transgenic rat strain with tissue-specific silencing of AMPKα1 and 2.  These rats will be 
studied to determine if AMPK is involved in the oxygen-sensing capabilities of carotid 
body type I cells.
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Figure 4. Structure of virus producing tissue-specific silencing  
(A) Structure of the virus. (B) Diagram of recombination that would occur in tissues that 






















































II. MATERIALS AND METHODS 
 
Cloning and cell culture 
Restriction enzymes and buffers used in ligation experiments were purchased 
from Invitrogen (Carlsbad, CA) and used according to the manufacturer’s specifications.  
Digested vector DNA was dephosphorylated using Antarctic Phosphatase (New England 
Biolabs, Ipswich, MA, M0289S) prior to ligation.  Digested DNA was separated using 
agarose gel electrophoresis, and DNA fragments for ligation were isolated using an 
E.Z.N.A. Gel Extraction Kit (Omega Bio-Tek, Norcross, GA, D2501-01) according to the 
manufacturer’s specifications.  All ligations were performed using a rapid ligation kit 
(Roche, Basel, Switzerland, 11635379001) according to the manufacturer’s 
specifications.  Lentiviral plasmids were transformed into One Shot Stbl3 Chemically 
Competent Cells (Invitrogen, Carlsbad, CA, C7373-03) according to the manufacturer’s 
specifications.  Plasmid DNA was isolated from bacterial cultures using E.Z. Nucleic 
Acid Plasmid Mini (D6942-02) or Maxi (D6922-02) Kits from Omega Bio-Tek 
(Norcross, GA) according to the manufacturer’s specifications.  Sequences were verified 
by DNA sequencing (AGCT, Inc., Wheeling, IL).  Table 1 contains a summary of base 
plasmids used as starting materials for cloning.  Table 2 contains a summary of all cloned 




A multiple cloning site, or MCS, (ClaI-XbaI-NdeI-HindIII-EcoRV-EcoRI-PstI-
SmaI-SalI-XbaI-BamHI) was purchased as DNA oligonucleotides from IDT, Inc. 
(Coralville, IA), annealed, and ligated into pLenti6/V5 D-TOPOTM (Invitrogen, Carlsbad, 
CA, K4955-01) containing an enhanced green fluorescent protein (GFP) gene using ClaI 
and BamHI to create pLv-MCS-GFP.   
 
The rat tyrosine hydroxylase promoter was isolated from 4.5ThpAL+ (provided 
by Dr. Karen O’Malley, Washington University School of Medicine) using EcoRV and 
EcoRI and cloned into the MCS to create pLv-MCS-THp-GFP.  This construct was used 
to generate a stable pool of HEK293 cells expressing GFP under control of the TH 
promoter.   
 
The GFP gene was removed from pLv-MCS-GFP using BamHI and ApaI, and the 
sticky ends were removed by blunting with a Quick Blunting Kit (New England Biolabs, 
Ipswich, MA, E1202L) according to the manufacturer’s specifications.  The blunt ends 
were ligated together to create pLv-MCS-∆GFP.  The TH promoter was cloned into this 
construct using EcoRV and EcoRI to create pLv-MCS-THp-∆GFP.   
 
The Cre recombinase gene with a Myc tag was isolated from pCAG-CreMyc 
(purchased from Addgene, Inc., Cambridge, MA) using polymerase chain reaction (PCR) 
(Platinum Taq DNA Polymerase High Fidelity, Invitrogen, Carlsbad, CA, 11304-011) 
according to the manufacturer’s specifications.  Primers were purchased from IDT, Inc. 
(Coralville, IA).  The PCR reaction added EcoRI sites to both ends of CreMyc, and a 
18 
 
HindIII site was added to the 3’ end inside the EcoRI site.  EcoRI was used to clone the 
CreMyc PCR product into pLv-MCS-THp-∆GFP to create pLv-MCS-THp-CreMyc.  
This construct was used to generate a stable pool of HEK293 cells expressing CreMyc 
under control of the TH promoter.   
 
RNA oligonucleotides for siRNA experiments and DNA oligonucleotides for 
shRNA experiments were synthesized by ACGT, Inc. (Wheeling, IL).  DNA oligos were 
annealed and ligated into pENTRTM/U6 using the BLOCK-iTTM U6 RNAi entry vector 
kit (Invitrogen, Carlsbad, CA, K4944-00) according to the manufacturer’s instructions to 
create the plasmid shRNAs (pENTR-U6-AMPKα1&2shRNA Loops 2-4) and control 
shRNA (pENTR-U6-control shRNA loop 3).  pENTR plasmids were transformed in One 
Shot TOP10 Chemically Competent E. coli cells (Invitrogen, Carlsbad, CA, C4040-10) 
according to the manufacturer’s specifications.   
 
An RNA polymerase III stop site flanked by two LoxP sites (LoxP-Stop-ClaI-
XhoI-LoxP) was purchased as DNA oligonucleotides with 5’ phosphorylated overhangs 
complementary to NdeI sticky ends from IDT, Inc. (Coralville, IA) and annealed.  The 
annealed oligo contained overhangs that could be directly ligated into the pENTR-U6-
AMPKα1&2shRNA-Loop3 plasmid digested with NdeI to create pENTR-U6-LoxP-
AMPKα1&2shRNA-Loop3.  Successful ligation of the oligo into the NdeI site of the 
vector removed the NdeI site, and the ligated DNA was digested with NdeI prior to 
transformation to remove religated vector DNA.  To test the recombination, pENTR-U6-
LoxP-AMPKα1&2shRNA-Loop3 DNA was recombined with Cre recombinase (New 
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Table 1.  Base plasmids used to create constructs 
 Plasmid name: Use: 
pLv-CMV-GFP Base plasmid for TH 
promoter-driven constructs 
4.5ThpAL+ Source of rat TH promoter 
to drive expression of GFP 
and CreMyc 
pCAG-CreMyc Source of CreMyc DNA to 
be cloned into TH 
promoter-driven construct, 
ubiquitously expressed 
CreMyc for control in 
transfection 
pEGFP Ubiquitously expressed 
CMV promoter-driven 






Table 2.  Cloned constructs 
Plasmid name: Backbone: Cloning strategy: Use: Status: 
pLv-MCS-GFP pLenti6 CMV in pLv-CMV-
GFP replaced with 
MCS 
Base plasmid for 
TH promoter-





pLenti6 TH promoter cloned 
in front of GFP in 
pLv-MCS-GFP 
Used to make TH 
promoter-driven 
GFP virus for 
infection and as 
TH promoter-
driven GFP for 




pLenti6 GFP gene removed 
from pLv-MCS-GFP  






pLenti6 TH promoter cloned 
into pLv-MCS-∆GFP 






pLenti6 CreMyc PCR product 
from pCAG-CreMyc 
cloned after TH 
promoter 
TH promoter-
driven CreMyc for 












shRNA loop 3 
pENTR/U6 LoxP oligo ligated 










pENTR/U6 MCS cloned after 
shRNA 







pENTR/U6 THp-CreMyc from 
pLv-MCS-THp-
CreMyc cloned after 
shRNA 















construct cloned into 
lentiviral backbone 
Lentiviral plasmid 







England Biolabs, Ipswich, MA, M0298S) according to the manufacturer’s specifications, 
digested with XhoI and PvuII, and electrophoresed on a 1% agarose gel.   
 
NIH3T3, HEK293, and PC12 cells were purchased from ATCC, Inc. (Manassas, 
VA), and maintained at 37oC supplemented with 5% CO2 in HyClone DMEM/High 
glucose (Thermo Scientific, Waltham, MA, SH30022.01) with 10% FBS (Biowest, 
Nuaillé, France, S01520) and 1% HyClone antibiotic/antimycotic solution (Thermo 
Scientific, Waltham, MA, SV30079.01).  Cells were passaged at 90% confluency.   
 
siRNA and shRNA design 
 cDNA sequences of human, mouse, and rat AMPKα1 and AMPKα2 were aligned 
using MacVector software.  The sequence ATGATGTCAGATGGTGAATTT was 
identified in the NCBI database (http://www.ncbi.nlm.nih.gov/index.html) and 
determined to be 100% identical in all cDNAs and corresponded to the following 
nucleotide regions: hAMPKα1 (gene accession number Q96E92) 553-573, mAMPKα1 
498-518, rAMPKα1 487-507, hAMPKα2 558-578 (gene accession number P54646.2), 
mAMPKα2 596-616, rAMPKα2 494-514).  The global siRNA and shRNA were 
designed to target this region.  A second sequence, AATGGAATATGTGTCTGGAGG, 
was 100% conserved in the cDNA sequences of human, mouse, and rat AMPKα2.  This 
region contains two base pair mismatches with the mouse and rat AMPKα1 sequences 
and three base pair mismatches with the human AMPKα1 sequence.  A control shRNA 
was designed to be identical to the AMPKα1 and 2 shRNA with the exception of 5 base 
pair mismatches.  The sequence of the control shRNA 
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(ACGACGTCAGCTGGTGCATGT) did not contain significant homology to known 
genes in the human, mouse, or rat genomes as determined by analysis in the 
NCBI/BLAST program.  shRNA stem loop design was based upon previous studies 
[TLB unpublished data, 27].   
 
Transfection and infection 
HEK293 cells were seeded on 60 mm plates at 1.2x106 cells/plate and transfected 
with a 3:1 ratio of Lipofectamine2000 (Invitrogen, Carlsbad, CA, 11668019) to DNA 
according to the manufacturer’s specifications.  NIH3T3 cells were simultaneously 
seeded on 60 mm plates at 8x105 cells/plate and transfected with a 5:1 ratio of 
Metafectene (Biontex, San Diego, CA, T020-1.0) to DNA according to the 
manufacturer’s specifications.  Transfection efficiency was determined by replicate 
transfection with ubiquitously expressed GFP (pEGFP).  Cells were lysed 24, 48, or 72 
hours post- siRNA transfection and 72 hours post-shRNA (pENTR-U6-AMPKα1&2 
shRNA Loops 2-4) transfection for analysis.  Stable pools were generated by treating 
transfected HEK293 cells (transfected with pLv-MCS-THp-GFP or pLv-MCS-THp-
CreMyc) with 10 µg/ml Blasticidin (InvivoGen, San Diego, ant-bl-1).  PC12 cells were 
seeded on 60 mm plates at 5x104 cells/plate and infected by adding 2 ml of lentiviral 
THp-GFP (made from pLv-MCS-THp-GFP plasmid) for 24 hrs.  Cells were maintained 







 Whole cell lysates were collected with Cell Lysis Buffer (Cell Signaling, Beverly, 
MA, 9803) supplemented with Complete Protease Inhibitor Tablets (Roche, Basel, 
Switzerland, #11836153001).  Lysates were briefly sonicated on ice, and protein 
concentrations were determined by the Bradford method [41-42].  Lysates were boiled in 
Laemmli reducing buffer, and 50 µg of total protein from each sample was 
electrophoresed on 10% SDS polyacrylamide gels for AMPK isolation or 8% SDS 
polyacrylamide gels for ACC isolation.  Proteins were transferred to an Immobilon 
PVDF Membrane (Millipore, Billerica, MA, IPVH08100) and blocked in Tris-buffered 
saline containing 0.1% Tween-20 and 5% nonfat, dry milk.  Antibodies purchased from 
Cell Signaling (Beverly, MA, anti-AMPKα1 #2795; anti-AMPKα #2603; anti-phospho-
ACC #3661; anti-ACC #3676) were used overnight at a dilution of 1:1000 in Tris-
buffered saline with 0.1% Tween-20 and 5% bovine serum albumin.  Antibodies 
purchased from GeneTex (San Antonio, TX, anti-AMPKα2,GTX111373) were used 
overnight at a dilution of 1:2000 in Tris-buffered saline with 0.1% Tween-20 and 5% 
nonfat, dry milk.  Anti-actin C4 monoclonal antibody (Seven Hills Bioreagents, 
Cincinnati, OH) was used at a 1/10,000 dilution for 1 hr at room temperature.  Anti-Myc 
antibody (clone 9E10) was purchased from Millipore, Inc. (Billerica, MA).  Horseradish 
peroxidase-conjugated secondary antibodies were purchased from Promega (Madison, 
WI, anti-rabbit IgG, HRP conjugate #W401B; and anti-mouse IgG, HRP-conjugate 
#W402B) and used at a dilution of 1:25,000 for one hour.  Blots were developed using 
SuperSignal West Pico Chemiluminescent Substrate kit (Thermo Scientific, Waltham, 





 Western blot data was analyzed with NIH ImageJ software (rsbweb.nih.gov/ij/) to 
quantitate protein levels.  For shRNA experiments, three to six independent experiments 
were performed for each blot, and the results were averaged.  Statistical significance was 








siRNA-mediated knockdown of AMPK alpha 
AMPKα was first knocked down using siRNA in order to identify viable 
sequences that can be targeted with an shRNA to generate stable knockdown.  To 
generate a global AMPKα1 and 2 gene knockdown, we aligned the cDNA sequences of 
human, mouse, and rat AMPKα1 and 2 and identified a single 21 bp sequence conserved 
in each (Table 3).  We generated an siRNA targeting this sequence to determine if it 
could knock down AMPKα1 and AMPKα2 simultaneously.  We also made an siRNA 
against a region of AMPKα2 that is conserved in human, mouse, and rat (Table 4).  The 
siRNAs were transfected in mouse fibroblast cells, NIH3T3s, at two different 
concentrations, and the cells were lysed 24, 48, and 72 hours post-transfection and run on 
a western blot (Figure 5).  The lower concentration, 20 nm, was used to ensure there were 
few off-target effects.  The higher concentration, 100 nm, was used to ensure the greatest 
knockdown of the target protein.  The global siRNA knocked down AMPKα1 and 2 
protein levels at both concentrations at all three time points compared to mock-
transfected control.  The AMPKα2 siRNA caused a moderate knockdown of AMPKα1 
and 2.  Surprisingly, it caused a greater knockdown of AMPKα1 than AMPKα2 though 
the siRNA was not a perfect match for AMPKα1.  The transient nature of siRNA- 
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Table 3. Identification of a globally conserved sequence in AMPK alpha 1 and 2 
AMPKα1 Human AAC ATG ATG TCA GAT GGT GAA TTT TTA 
Mouse AAC ATG ATG TCA GAT GGT GAA TTT TTA 
Rat AAC ATG ATG TCA GAT GGT GAA TTT TTA 
AMPKα2 Human AAT ATG ATG TCA GAT GGT GAA TTT CTG 
Mouse AAT ATG ATG TCA GAT GGT GAA TTT CTA 
Rat AAT ATG ATG TCA GAT GGT GAA TTT CTA 
AMPKα1&2 global siRNA         ATG ATG TCA GAT GGT GAA TTT 
 
cDNA sequences for human, mouse, and rat AMPKα1 and α2 were aligned using the 
MacVector software program.  Mismatches are shown in bold. 
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Table 4. Identification of a conserved sequence in AMPK alpha 2 
AMPKα1 Human GGT GAT GGA ATA TGT CTC AGG AGG AGA 
Mouse GGT GAT GGA ATA TGT CTC TGG AGG AGA 
Rat GGT GAT GGA ATA TGT CTC TGG AGG AGA 
AMPKα2 
 
Human GGT AAT GGA ATA TGT GTC TGG AGG TGA 
Mouse GGT AAT GGA ATA TGT GTC TGG AGG TGA 
Rat GGT AAT GGA ATA TGT GTC TGG AGG TGA 
AMPKα2 specific siRNA          AAT GGA ATA TGT GTC TGG AGG  
 
cDNA sequences for human, mouse, and rat AMPKα1 and α2 were aligned using the 
MacVector software program.  Mismatches are shown in bold. 
28 
 
Figure 5. siRNA-mediated knockdown of AMPK alpha 1 and 2 in NIH3T3 cells 
(A) Western blots of NIH3T3 cells transfected with AMPKα2 or AMPKα1&2 siRNA at 
20 nM or 100 nM.  Cells were lysed after 24 hrs, 48 hrs, or 72 hrs and separated with 
SDS-PAGE.  Blots were probed with anti-AMPKα1, anti-AMPKα2, and anti-actin.  
Representative actin blot shown in A.  (B-C) Relative AMPKα1 (B) and AMPKα2 (C) 
protein levels in siRNA-transfected NIH3T3 cells compared to mock-transfected control 
cells 24, 48, and 72 hours post-transfection after normalizing to actin loading control.  
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mediated knockdown is evident in Figure 5 as a less efficient knockdown 72 hrs after 
transfection.  These results prompted us to select the sequence of the global AMPKα1 
and 2 siRNA to generate an shRNA that can be used to stably knock down AMPKα1 and 
2. 
 
shRNA-mediated knockdown of AMPK alpha 
 To generate stable knockdown of AMPKα1 and 2, we used the AMPKα1 and 2 
siRNA sequence to generate an shRNA.  Though the loop structure of the shRNA is 
cleaved prior to binding of the RNA to the target mRNA, the sequence of the loop has a 
significant impact on the activity of the shRNA [43].  We will refer to the most 
commonly used shRNA loop sequence (TTCAAGAGA) as the Brummelkamp loop [29].  
However, this particular loop begins with two thymidine residues.  RNA polymerase III, 
which drives shRNA production from the U6 promoter in the pENTRTM vector, 
recognizes a stretch of four or more thymidine residues as a stop site [44].  Therefore, this 
loop cannot be used if the stem sequence of the shRNA ends in two or more thymidine 
residues, as is the case for the AMPKα1 and 2 shRNA.  For this reason, we needed to 
identify different loop sequences that did not begin with thymidine (Table 5).  We tested 
three loops, referred to as loops 2-4, in NIH3T3 cells (Figure 6).  A fourth loop, loop 1 
was not tested because the plasmid was found to contain a mutation after sequencing.  
Two of the loops, loops 3 and 4, significantly knocked down protein levels of both 
isoforms of AMPKα.  Loops 3 and 4 were the complement and the reverse, respectively, 
of the Brummelkamp loop.  We found that the complement of the Brummelkamp loop,  
31 
 
Table 5.  Design of shRNA loop sequences and sequences of shRNA oligos 
Brummelkamp loop TTCAAGAGA 
Loop 2 CCACACC 
Loop 3 AAGTTCTCT 
Loop 4 AGAGAACTT 
Loop 2 top oligo CACCGATGATGTCAGATGGTGAATTTCC
ACACCAAATTCACCATCTGACATCAT 
Loop 2 bottom oligo AAAAATGATGTCAGATGGTGAATTTGGT
GTGGAAATTCACCATCTGACATCATC 
Loop 3 top oligo CACCGATGATGTCAGATGGTGAATTTAA
GTTCTCTAAATTCACCATCTGACATCAT 
Loop 3 bottom oligo AAAAATGATGTCAGATGGTGAATTTAGA
GAACTTAAATTCACCATCTGGACATCATC 
Loop 4 top oligo CACCGATGATGTCAGATGGTGAATTTAG
AGAACTTAAATTCACCATCTGACATCAT 
Loop 4 bottom oligo AAAAATGATGTCAGATGGTGAATTTAAGT
TCTCTAAATTCACCATCTGACATCATC 
 
Loop sequences and sequences of DNA oligos ordered from ACGT, Inc., and ligated into 
pENTRTM to create plasmid shRNAs.
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Table 6.  Design of global AMPK alpha 1 and 2 shRNA and corresponding control 
shRNA 
AMPKα1&2 Loop 3 shRNA sequence 
ATG ATG TCA GAT GGT GAA TTT 
                 
TAC TAC AGT CTA CCA TCC AAA  
Control shRNA sequence 
ACG ACG TCA GCT GGT GCA TGT 
 
TGC TGC AGT CGA CCA CGT ACA 
 
Base pair mismatches in the control shRNA are shown in bold. 
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Figure 6.  shRNA-mediated knockdown of AMPK alpha 1 and 2 in NIH3T3 cells 
with different loop sequences 
(A) Representative western blot of NIH3T3 cells transfected with AMPKα1 and 2 
shRNA with loops 2-4 and control shRNA.  Cells were lysed after 72 hrs.  Lysates were 
electrophoresed with SDS-PAGE and immunoblotted with anti-AMPKα1, anti-
AMPKα2, and anti-actin.  (B) Relative AMPKα1 and 2 protein levels in shRNA-
transfected NIH3T3 cells compared to control shRNA-transfected NIH3T3 cells after 
normalizing to actin loading control.  Relative protein levels are listed as percentages of 
control.  Results are representative of 3 independent experiments.  Data was analyzed 
with NIH ImageJ software.  Error bars represent the standard error of the mean.  (*) 



























loop 3, resulted in the greatest knockdown, 54% knockdown of AMPKα1 and 55% 
knockdown of AMPKα2, and this shRNA was chosen for further study.  We created a 
control shRNA containing five base-pair mismatches from the target 21 nt siRNA 
sequence using the loop 3 sequence (Table 6).  AMPKα1 and 2 protein levels in cells 
transfected with the control shRNA were equivalent to mock-transfected controls (data 
not shown).  This control shRNA was used for all shRNA experiments.   
 
Knockdown of AMPK alpha in mouse and human cells 
We transfected the shRNA into mouse NIH3T3 cells and human embryonic 
kidney HEK293 cells to demonstrate its ability to knock down AMPKα1 and 2 in 
multiple species (Figure 7).  The shRNA significantly knocked down protein levels of 
both isoforms of AMPKα in both species.  In mouse NIH3T3 cells, AMPKα1 and 
AMPKα2 protein levels were knocked down 49% and 44%, respectively, compared to 
the control shRNA.  In human HEK293 cells, AMPKα1 and AMPKα2 protein levels 
were knocked down 63% and 72%, respectively, compared to the control shRNA.  The 
shRNA was likely more effective in human cells than in mouse cells due to the increased 
transfection efficiency in HEK293 cells, as determined by replicate transfections with 
GFP.  Representative fluorescence micrographs of NIH3T3 and HEK293 cells 
transfected with GFP are shown in Figure 8 to demonstrate the difference in transfection 
efficiency between the cell types. Both transfections were performed as controls during 
shRNA experiments simultaneously and under the same conditions as the shRNA 




 Figure 7.  shRNA-mediated knockdown of AMPK alpha 1 and 2 in mouse and 
human cells 
(A) Representative western blot of NIH3T3 and HEK293 cells transfected with AMPKα1 
and 2 loop 3 shRNA and control shRNA.  Cells were lysed after 72 hrs.  Lysates were 
electrophoresed with SDS-PAGE and immunoblotted with anti-AMPKα1, anti-
AMPKα2, and anti-actin.  (B-C) Relative AMPKα1 and 2 protein levels in shRNA-
transfected NIH3T3 cells (B) and HEK293 cells (C) compared to control shRNA-
transfected cells after normalizing to actin loading control.  Relative protein levels are 
listed as percentages of control.  Results are representative of 3-6 independent 
experiments.  Data was analyzed with NIH ImageJ software.  Error bars represent the 
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Figure 8.  Transfection efficiency of NIH3T3 and HEK293 cells 
(A-B) Representative fluorescence micrographs of NIH3T3 cells (A) and HEK293 cells 
(B) transfected with ubiquitously expressed CMV promoter-driven GFP (pEGFP) as 
replicate controls for shRNA transfection experiments.  Fluorescence was checked after 














Functional knockdown of AMPK alpha 
 To show functional knockdown of AMPK by the loop 3 shRNA, we looked for 
reduced phosphorylation of a direct target, acetyl-CoA carboxylase (ACC).  Transfection 
of HEK293 cells with the loop 3 AMPKα1 and 2 shRNA did not alter total ACC protein 
levels; however, it did cause a significant reduction in the phosphorylated form of ACC 
(phospho-ACC, Figure 9).  The protein level of phosphorylated ACC was knocked down 
41% by the AMPKα1 and 2 shRNA compared to the control shRNA.  The total ACC 
protein levels in the AMPKα1 and 2 shRNA-treated cells compared to the control 
shRNA-treated cells were nearly identical and unaffected by transfection.   
 
Expression of TH promoter-driven constructs 
 To test the expression of the tyrosine hydroxylase promoter-driven GFP plasmid 
(pLv-MCS-THp-GFP), we transfected HEK293 cells and selected with blasticidin to 
generate a stable pool of transfected cells.  The cells expressed GFP (Figure 10 A), 
indicating the construct is functional.  HEK293 cells express TH [45], even though they 
were isolated from kidney cells, because they have been found to more closely resemble 
neuronal cells than kidney cells [46].  The TH promoter-driven GFP was also expressed 
in PC12 cells (Figure 10 B), which are rat pheochromocytoma cells that express TH [47].  
HEK293 cells were transfected with the TH-driven CreMyc plasmid (pLv-MCS-THp-
CreMyc) and selected with blasticidin to generate a stable pool of cells.  The extracts 
from these cells were run on a western blot along with positive control lysates of 
HEK293 cells transiently transfected with the ubiquitously expressed CreMyc plasmid 
(pCAG-CreMyc) (Figure 10 C).  Both transfected cell populations expressed CreMy
41 
 
Figure 9.  shRNA-mediated knockdown of AMPK alpha activity in HEK293 cells  
(A) Representative western blot of HEK293 cells transfected with AMPKα1 and 2 loop 3 
shRNA and control shRNA.  Cells were lysed after 72 hrs.  Lysates were electrophoresed 
on an 8% SDS-PAGE gel and immunoblotted with anti-phospho-ACC, anti-ACC, and 
anti-actin.  Lysates from one experiment were also electrophoresed on a 10% SDS-PAGE 
gel and immunoblotted with anti-AMPKα and anti-actin.  (B) Phospho-ACC protein 
levels in shRNA-transfected HEK293 cells compared to control shRNA-transfected cells 
as a percentage of total ACC levels after normalizing to actin loading control.  Relative 
protein levels are listed as percentages of control.  Results are representative of 3 
independent experiments.  Data was analyzed with NIH ImageJ software.  Error bars 






















Figure 10.  Expression of TH promoter-driven constructs 
(A) Fluorescence micrograph of HEK293 cells transfected with TH promoter-driven GFP 
plasmid (pLv-MCS-THp-GFP).  Transiently transfected cells were selected with 10 
µg/ml Blasticidin to generate a stable pool of transfected cells.  (B) Fluorescence 
micrograph of PC12 cells infected with TH promoter-driven GFP lentivirus.  (C) Western 
blot of HEK293 cells transfected with TH promoter-driven CreMyc plasmid (pLv-MCS-
THp-CreMyc) and ubiquitously expressed CreMyc plasmid (pCAG-CreMyc).  Cells were 
lysed after 72 hrs.  Lysates were electrophoresed on a 10% SDS-PAGE gel and 




















(38 kDa), and all HEK293 cell populations did not express endogenous Myc (49 kDa) as 
expected [48].  
 
Cre recombinase-driven recombination 
The U6 promoter was disrupted with two LoxP sites flanking an RNA polymerase 
III stop site.  The DNA was tested with recombinant Cre to ensure the floxed sequence 
was removed.  The recombined DNA was digested with XhoI and PvuII and 
electrophoresed on an agarose gel to determine the size of the resulting fragments (Figure 
11).  The recombination removed 52 bp, including the XhoI site, from the DNA.  This 
can be seen in the gel as a decrease in the amount of 770 and 279 bp fragments and the 
appearance of a 997 bp fragment (indicated with an arrow).  The reaction is reversible, so 
the reaction proceeds to equilibrium.  The banding pattern indicates the recombination 





Figure 11.  In vitro recombination of disrupted U6 promoter construct with Cre 
recombinase 
Agarose gel of pENTR-U6-LoxP-AMPKα1&2shRNA Loop 3 construct recombined with 
Cre recombinase. Lane 1 contains a ladder. Lanes 2 and 3 contain pENTR-U6-LoxP-
AMPKα1&2shRNA DNA digested with XhoI and PvuII. Lane 3 was recombined with 



















AMPK alpha 1 and 2 knockdown 
AMPK is a key regulator of cellular metabolism, and it exerts its function through 
the catalytic alpha subunit.  Knocking down both isoforms of the catalytic subunit is a 
way to study the function of AMPK; however, previous knockdowns of AMPKα were 
only designed to be effective in one model system.  We originally tested an shRNA 
against AMPKα1 and 2 that had been previously published [34], but the target sequence 
was not conserved between multiple species.  Therefore, we were unable to test the 
knockdown in a convenient system.  This led us to develop an siRNA that can target both 
catalytic α1 and α2 isoforms of AMPK in human, mouse, and rat cells.  This new siRNA 
could be used in any number of systems because the sequence is conserved.  Because 
siRNA only causes a transient knockdown in protein levels, we converted the siRNA into 
an shRNA.  The shRNA caused a significant reduction in AMPKα protein levels in both 
human and mouse cells.  We hypothesize the shRNA will also be effective in rat cells 
because the sequence is 100% conserved.   
 
When designing an shRNA, the loop that is used can have a significant impact on 
the knockdown of the target protein [43].  We chose to test three different loops to 
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determine which is the most effective.  The complement of the most commonly reported 
loop (loop 3) was found to be the most effective.  This loop can be used for shRNAs that 
end in thymidine residues as an alternative to the most common loop to prevent the 
formation of an RNA polymerase III stop site.   
 
The shRNA was cloned into the pENTRTM/U6 Entry vector from Invitrogen.  
From this plasmid, the shRNA can be transferred into other expression systems such as 
the lentiviral Block-iTTM Dest vector from Invitrogen, which can be used to make a 
lentivirus containing the shRNA.  Lentiviral infection with the shRNA should cause 
greater knockdown due to a higher efficiency of transduction.   
 
Knockdown of protein levels does not necessarily correspond to a reduction in 
activity of the target protein.  For this reason, we wanted to ensure AMPKα activity was 
also reduced by the shRNA.  ACC is phosphorylated at Ser79 by AMPKα [49].  ACC 
catalyzes the production of malonyl-CoA from acetyl-CoA, thus providing the starting 
material for fatty acid synthesis.  When ATP is depleted from the cell, ACC is inactivated 
by AMPK, and acetyl-CoA is used for energy production in the citric acid cycle.  The 
reduction in phospho-ACC levels indicates that AMPK activity, not just protein levels, 
was reduced by the shRNA.   
 
Tissue-specific constructs 
The tyrosine hydroxylase promoter will be used to generate tissue-specific 
expression of the shRNA.  A plasmid containing TH promoter-driven GFP was generated 
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to visualize where the TH promoter was expressed.  GFP was expressed in HEK293 and 
PC12 cells, which are TH positive, so the promoter is functional.  Also, the PC12 cells 
were infected with a lentivirus containing TH promoter-driven GFP.  This lentivirus was 
over 12 kb in size.  The generally accepted size limit for a lentivirus to be efficiently 
packaged into viral particles is about 10 kb.  The expression of GFP in these cells 
indicates that a larger virus is still capable of being effectively packaged and infecting 
cells.  This is important because the final virus will be about 12 kb, so we would expect 
the final virus to be functional from this result.   
 
A plasmid containing TH promoter-driven Cre recombinase with a Myc tag (pLv-
MCS-THp-CreMyc) was generated to direct tissue-specific expression of Cre 
recombinase.  Cre, when used with the shRNA with a disrupted promoter, will restore the 
promoter and allow the shRNA to be made in TH positive cells only.  The Myc tag was 
detected in lysates of a stable pool of HEK293 cells transfected with pLv-MCS-THp-
CreMyc, indicating the plasmid is functional.   
 
Disrupted U6 promoter 
The U6 promoter of the shRNA was disrupted by a floxed sequence of DNA 
containing an RNA polymerase III stop site.  The cloning to create this construct was 
challenging because the floxed sequence of DNA was ordered as small, approximately 90 
bp, DNA oligos that were annealed and digested before ligation into the NdeI site of the 
vector.  The small size of the insert and the lack of directional cloning made the reaction 
very unfavorable.  To overcome this issue, we designed oligos that would have overhangs 
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following annealing that are complementary to the NdeI site in the vector.  The oligos 
were synthesized with phosphorylated 5’ ends, which are required by DNA ligase, to 
allow them to be ligated directly into the digested vector following annealing.  Ligation 
of this oligo into the vector would remove the NdeI site in the vector, so we were able to 
digest the ligated DNA with NdeI before transformation to get rid of any vector DNA 
that religated with itself.  This strategy selected for successful ligations and removed the 
large amount of background vector religation.  The floxed sequence of DNA was 
removed from the promoter in vitro following treatment with Cre recombinase.  This 
indicates the floxed sequence is able to be removed as expected, and the promoter should 
be restored following expression of Cre recombinase.   
 
Future work 
In the future, the HEK293 cells stably expressing TH promoter-driven CreMyc 
will be transfected with the shRNA with a disrupted promoter to test the recombination 
mediated by Cre to determine if the U6 promoter function is restored following excision 
of the floxed sequence.  The TH-driven plasmids must also be tested to ensure they are 
truly tissue specific and are not expressed in TH negative cells.  In order to make the final 
virus, the cassette containing the TH promoter-driven Cre recombinase will be transferred 
to the same vector as the shRNA with the disrupted promoter.  
 
The construct with the disrupted promoter must still be tested to determine if the 
shRNA is no longer expressed.  If the floxed sequence of DNA is not sufficient to disrupt 
the U6 promoter, and there is still some expression of the shRNA, a GFP reporter gene 
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can be cloned into the sequence.  This reporter gene is very large and will effectively 
prevent transcription from the promoter.  The construct with the disrupted promoter must 
also be tested to determine if the shRNA is expressed after recombination with Cre 
recombinase.  Following recombination with Cre, one 34 basepair LoxP site remains in 
the DNA.  The distance between crucial elements of the U6 promoter is critical to its 
proper function, but the sequence of DNA between the elements is not [50].  If the extra 
DNA from the LoxP site prevents efficient binding of RNA polymerase III to the restored 
U6 promoter, an alternate strategy is to remove part of the U6 promoter so the LoxP site 
remaining after recombination replaces it.  This should ensure the promoter will be 
functional following recombination.   
 
In future studies, the tissue-specific shRNA will be used to generate a rat 
transgenic strain with knockdown of AMPKα1 and 2 only in cells that express TH.  A 
lentivirus containing both the shRNA with the disrupted U6 promoter and the TH 
promoter-driven Cre recombinase will be used to infect fertilized rat embryos.  A 
technique called embryo transfer will be used to transplant the infected embryos into 
pseudopregnant mothers [51-52].  The pups will have the transgene integrated into every 
cell, but the shRNA will only be made in cells that express TH.  Therefore, the rats will 
have tissue-specific knockdown of AMPKα1 and 2.  We expect the knockdown should 
not result in embryonic lethality because it is not a complete knockout, so some AMPKα 
protein is still made, and it is only knocked down in some tissues.  Previously, a mouse 
strain with total body knockout of AMPKα1 and liver-specific knockout of AMPKα2 
was generated [3,18].  The mice were viable, so this indicates that tissue-specific double 
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knockout models are possible, although it is currently not known which tissues require 
expression of AMPKα1 and 2 for survival of the animals.  It is also important to 
remember that the rats will have knockdown of AMPKα1 and 2, not knockout.  It is 
possible that minimal expression of AMPKα1 and 2 could allow the animals to survive.  
If the animals are not viable, an alternative is to use a conditional expression system, such 
as a Tet-On system [53], to control the temporal expression of Cre recombinase.  Using 
this system, Cre recombinase would not be expressed in TH-positive tissues until the 
animals are treated with the antibiotic tetracycline or a derivative, doxycycline.  In this 
way, knockdown of AMPK would not occur until after the animals are already born, so 
defects in development would be avoided.  The rats will be used in future studies to 
determine if breathing regulation by carotid body type I cells is impaired by knockdown 
of AMPK.  If AMPK is necessary for carotid body type I cells to respond to hypoxia, the 
rats will not be able to upregulate their breathing rate in response to hypoxia.  These 
studies will help elucidate the role of AMPK in oxygen sensing by the carotid body.   
  
In conclusion, we have generated a new shRNA that can significantly knock 
down protein levels and activity of AMPKα1 and 2 in multiple species.  This shRNA will 
later be used to generate a transgenic rat strain with tissue-specific knockdown of 
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